Pharmacoepidemiology for nephrologists (part 1): concept, applications and considerations for study design

Trevisan, M.; Fu, E.L.; Xu, Y.; Jager, K.; Zoccali, C.; Dekker, F.W.; Carrero, J.J.

doi:doi:10.1093/ckj/sfaa244

Persistent URL of this record https://hdl.handle.net/1887/3276454

View statistics

In Collections

This item can be found in the following collections:

Medicine / Leiden University Medical Centre (LUMC)

Trevisan, M.; Fu, E.L.; Xu, Y.; Jager, K.; Zoccali, C.; Dekker, F.W.; Carrero, J.J. (2021)

Pharmacoepidemiology for nephrologists (part 1): concept, applications and considerations for study design

Article / Letter to editor

Randomized controlled trials on drug safety and effectiveness are the foundation of medical evidence, but they may have limited generalizability and be unpowered to detect rare and long-term kidney outcomes. Observational studies in routine care data can complement and expand trial evidence on the use, safety and effectiveness of medications and aid with clinical decisions in areas where evidence is lacking. Access to routinely collected large healthcare data has resulted in the proliferation of studies addressing the effect of medications in patients with kidney diseases and this review provides an introduction to the science of pharmacoepidemiology to critically appraise them. In this first review we discuss the concept and applications of pharmacoepidemiology, describing methods for drug-utilization research and discussing the strengths and caveats of the most commonly used study designs to evaluate comparative drug safety and effectiveness.